Immutep


Immutep S.A. is a biopharmaceutical company developing immunotherapeutics in oncology. Our products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer. The Company's technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response.


Interview Frederic Triebel, founder, Immutep, with PharmaTelevision.

Get the Flash Player to see this video.





© 2002 Immutep, S.A.
Press Release
10/2014 - Immutep announces proposed acquisition by Prima BioMed Ltd
image Immutep announces today it has reached an agreement by which it will ...
04/2014 - Immutep and Eddingpharm start production of ImmuFact® IMP321 at WuXi AppTec in China
image Immutep S.A., the biopharmaceutical company specializing in ...
10/2013 - Immutep and Eddingpharm sign agreement for development of ImmuFact® IMP321 in China
image Immutep S.A., the biopharmaceutical company specializing in ...
04/2012 - Immutep and Lonza Sign Agreement for Cell Line Selection, Cell Banking and Process Development of ImmuFact® IMP321
image Immutep and Lonza announced today an agreement for cell line ...
02/2012 - Interview Frederic Triebel with PharmaTelevision
image Get the Flash ...